In NSCLC and liver cancer, for instance, it was demonstrated that p53 up-regulates PD-L1 via miR-34, which could serve as a predictive biomarker for PD-1 inhibitor immunotherapy [16, 17]. Here, PDCD1 is linked to non-small cell lung carcinoma.